Last16.48 -0.69 (-4.02%)
12.9 - 39.55
52 Week Range
Technical Indicators (Daily)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO
Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO). Such investors are advised to contact Robert S. Willoughby at ...
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in ...
The ARK Innovation ETF and ARK Genomic Revolution ETF cumulatively snapped up hundreds of thousands of shares in Crispr in the past week....
Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped....
Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) Intrinsic Value Is Potentially 96% Above Its Share Price
In this article we are going to estimate the intrinsic value of Allogene Therapeutics, Inc. ( NASDAQ:ALLO ) by......
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.